The UK inhalable drug market is anticipated to grow at a CAGR of 2.0% over the forecast period (2020-2026). The key aspect that drives the growth of the market includes the rising prevalence of various respiratory and non- respiratory diseases and the increasing geriatric population. Besides, the inclination of the people towards the sedentary lifestyle along with unhealthy eating habits such as smoking accelerates the prevalence of several respiratory diseases such as COPD and asthma, which ultimately aids in the growth of the market. In addition, increasing R&D and investments by big pharmaceutical companies in life science research along with innovations are likely to propel the growth of the market in the country.

A full Report of UK Inhalable Drugs Market Available at https://www.omrglobal.com/industry-reports/uk-inhalable-drugs-market

Further, recent developments by the companies in the country are also encouraging market growth. Some of the key players operating in the industry include F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca Plc, and others. The outbreak of COVID-19 has encouraged the manufacturers to develop novel drugs, including inhalable drugs. For instance, in July 2020, Synairgen Plc, a UK-based drug development company developed an inhaled formulation of interferon beta that aided in reducing the risk of developing severe diseases in COVID-19 patients. Thus, such launches and innovations by the players in the country are likely to encourage market growth.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/uk-inhalable-drugs-market

Market Coverage


• Market number available for – 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Application and By Route of Administration
• Country Covered- UK
• Competitive Landscape- Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Novartis AG, AstraZeneca Plc, and Synairgen Plc

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

UK Inhalable Drugs Market – Segmentation

By Application

• Respiratory Diseases
• Non- Respiratory Diseases

By Route of Administration

• Nasal
• Mouth

Company Profiles

• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Novartis AG
• Sanofi SA
• Synairgen Plc
• Vectura Group Plc
• Verona Pharma plc
• Zambon S.p.A.

For More Customized Data, Request for Report Customization https://www.omrglobal.com/report-customization/uk-inhalable-drugs-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404